Sanjiv Patel - Jan 21, 2025 Form 4 Insider Report for Relay Therapeutics, Inc. (RLAY)

Signature
/s/ Brian Adams, as Attorney-in-Fact
Stock symbol
RLAY
Transactions as of
Jan 21, 2025
Transactions value $
-$1,762,500
Form type
4
Date filed
1/23/2025, 07:01 PM
Previous filing
Jan 14, 2025
Next filing
Feb 13, 2025

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RLAY Common Stock Sale -$565K -125K -21.76% $4.52 450K Jan 21, 2025 By The Patel Family Irrevocable Trust of 2019 F1, F2, F3
transaction RLAY Common Stock Sale -$600K -125K -27.81% $4.80 325K Jan 22, 2025 By The Patel Family Irrevocable Trust of 2019 F1, F3, F4
transaction RLAY Common Stock Sale -$598K -125K -38.52% $4.78 200K Jan 23, 2025 By The Patel Family Irrevocable Trust of 2019 F1, F3, F5
holding RLAY Common Stock 766K Jan 21, 2025 Direct F6
holding RLAY Common Stock 687K Jan 21, 2025 By The SSP Irrevocable Trust of 2020 F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 These shares were sold by the Patel Family Irrevocable Trust of 2019 (the "Trust") pursuant to a Rule 10b5-1 trading plan adopted by the Trust on August 7, 2024.
F2 This transaction was executed in multiple trades at prices ranging from $4.35 to $4.62. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F3 These shares are held in the Trust for the benefit of the reporting person's family members. An independent trustee is trustee of the Trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
F4 This transaction was executed in multiple trades at prices ranging from $4.65 to $4.97. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F5 This transaction was executed in multiple trades at prices ranging from $4.62 to $4.89. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F6 Includes 762,360 shares underlying restricted stock units.
F7 These shares are held in an irrevocable trust for the benefit of the reporting person's family members. An independent trustee is trustee of the trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.